Public complaints and social media reports regarding questionable practices among wholesale pharmaceutical suppliers have seen a noticeable increase. Reports indicate that pharmacies attempting to purchase high-demand medications are frequently pressured into buying additional, unordered pharmaceutical products as a mandatory condition for completing transactions.

Official data from regulatory authorities reveals that hundreds of companies engaged in medical imports over the period, with a staggering concentration of market share. Specifically, a tiny fraction of the largest importers commands nearly half of the entire import volume, raising serious concerns regarding market monopolization and supply chain control.

Concurrently, ongoing structural shifts within the national pharmacy network have been documented. While thousands of retail and wholesale outlets operate nationwide, data points to a shrinking number of independent primary pharmacies contrasted against a rapid expansion of corporate branch networks.

Regulatory experts assert that forcing unwanted inventory onto retail buyers directly infringes upon the commercial interests of smaller business operators. Such restrictive practices allegedly distort standard market dynamics, stifle independent enterprise, and undermine fair competition across the pharmaceutical sector.

Under national competition legislation, the abuse of dominant market power and the imposition of unrequested supplementary conditions are strictly prohibited. Authorities have warned that if ongoing investigations substantiate these allegations, offending suppliers will face severe financial penalties proportional to their commercial turnover.

Source: podrobno.uz